<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5292">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03038048</url>
  </required_header>
  <id_info>
    <org_study_id>16-594E</org_study_id>
    <nct_id>NCT03038048</nct_id>
  </id_info>
  <brief_title>30g vs 33g Needle for Intravitreal Injections</brief_title>
  <official_title>Intravitreal Injection Using 33-gauge Versus 30-gauge Needles: Comparison of Patients' Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mid Atlantic Retina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are comparing the patient experience between the standard 30 g needle to the smaller 33 g
      needle for intravitreal injections of ranabizumab or aflibercept for age related macular
      degeneration, diabetic macular edema, or retina vein occlusions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, interventional pilot study, which seeks to compare the
      patient experience using 30-gauge versus 33-gauge needle for bilateral same-day intravitreal
      injections of ranibizumab or aflibercept for the treatment of wet age-related macular
      degeneration (AMD), diabetic macular edema (DME), or macular edema associated with retinal
      vein occlusion (RVO). The null hypothesis is that there is no difference in patient
      discomfort or pain with the 30-gauge needle compared to the 33-gauge needle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2017</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in discomfort between 30g and 33g needle</measure>
    <time_frame>Day 1</time_frame>
    <description>Intravitreal injection study pain questionnaire to evaluate discomfort associated with intravitreal injections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure 5 minutes post injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>33 g needle - right eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>33 g needle for intravitreal injection of Lucentis or Eylea for right eye and 30 g needle for left eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>33 g needle - left eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>33 g needle for intravitreal injection of Lucentis or Eylea for left eye and 30 g needle for right eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Varying needle size with intravitreal ranibizumab or aflibercept</intervention_name>
    <description>Varying gauge of needle, 33 gauge vs 30 gauge</description>
    <arm_group_label>33 g needle - right eye</arm_group_label>
    <arm_group_label>33 g needle - left eye</arm_group_label>
    <other_name>Lucentis, Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing bilateral, same-day, intravitreal injections of either
             ranibizumab oraflibercept for the diagnosis of wet AMD, DME, or RVO-associated
             macular edema

        Exclusion Criteria:

          -  1) Patients who do not receive Betadine ophthalmic solution prior to intravitreal
             injection due to documented allergy 2) Patients who are receiving intravitreal
             bevacizumab (this medication iscompounded into pre-filled 1-mL tuberculin syringes).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Chiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid Atlantic Retina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Formoso</last_name>
    <phone>215-928-3092</phone>
    <email>mformoso@midatlanticretina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly Diienno</last_name>
    <phone>215-928-3092</phone>
    <email>kdiienno@midatlanticretina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mid Atlantic Retina- Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Formoso</last_name>
      <phone>215-928-3092</phone>
      <email>mformoso@midatlanticretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly DiIenno</last_name>
      <phone>215-928-3092</phone>
      <email>kdiienno@midatlanticretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allen Chiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher Aderman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 9, 2017</lastchanged_date>
  <firstreceived_date>January 27, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>MidAtlantic Retina</investigator_full_name>
    <investigator_title>Allen Chiang, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
